658P - A retrospective analysis of the relation between durations of adjuvant chemotherapy with its effects on overall survival and relapse free survival...

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anti-Cancer Agents & Biologic Therapy
Gastric Cancer
Presenter Seong-Geun Kim
Citation Annals of Oncology (2014) 25 (suppl_4): iv210-iv253. 10.1093/annonc/mdu334
Authors S. Kim1, S. Hwang2
  • 1Hemato-oncology, Pusan National University Yangsan Hospital, 626-770 - Yangsan/KR
  • 2Surgery, Pusan National University Yangsan Hospital, 626-770 - Yangsan/KR

Abstract

Aim

This study was conducted to propose the optimal duration of adjuvant chemotherapy in stage II or III gastric cancer regardless of treatment regimens, which had been introduced from the oral fluoropyrimidine derivatives to the intravenous fluoropyrimidine combined with platinums.

Methods

We retrospectively analyzed data from 2198 patients with histologically confirmed gastric cancer who underwent curative gastrectomy with D2 lymphadenectomy between 2005 and 2012. 1347 patients (61.3 %) were treated by surgery alone due to early stage or patients' refusal of chemotherapy and 851 patients (38.7%) of stage II or III gastric cancer were treated with diverse durations and various kinds of adjuvant chemotherapy. The duration of adjuvant chemotherapy less than 6 months [Group 1] was 343 patients (40.3%), from 6 months to less than 12 months [Group 2] was 179 patients (21.0%), from 1 year to less than 2 years was [Group 3] 240 patients (28.2%) and over 2 years [Group 4] was 89 patients (10.5%).

Results

Overall survival (OS) and relapse free survival (RFS) were analyzed according to durations of adjuvant chemotherapy. Median follow-up duration was 3.82 years. Each median OS in Group 1, 2, 3, and 4 was 3.07 years (reference), 3.24 years (hazard ratio [HR] 1.019, 95% CI, 0.520 to 1.997, p-value 0.956), 4.06 years (HR 0.485 95% CI, 0.243 to 0.966, p-value 0.040*) and 4.87 years (HR 0.368, 95% CI, 0.128 to 1.058, p-value 0.064). Each median RFS in Group 1,2,3 and 4 was 2.68 years (reference), 3.06 years (HR 0.948, 95% CI, 0.484 to 1.854, p-value 0.875), 4.02 years (HR, 0.494 95% CI, 0.248 to 0.985, p-value 0.045*) and 4.76 years (HR, 0.392 95% CI, 0.136 to 1.127, p-value 0.082). * p < 0.05.

Conclusions

We concluded that a prospective cohort study should be performed to figure out the longer period of adjuvant chemotherapy in gastric cancers could obtain much higher OS and RFS.

Disclosure

All authors have declared no conflicts of interest.